Back to search results
NCT07221162

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

Active, Not Recruiting
PHASE1Ages 18–64InterventionalPrevention
National Institute of Allergy and Infectious Diseases (NIAID)
~140 participants
Updated 2026-06-23 on ClinicalTrials.gov
What's tested:Aluminum Hydroxide SuspensionBoost-2867CpG 7909Sodium Chloride, 0.9%

At a glance

Recruiting sites
0 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Occurrence of abnormal clinical safety laboratory adverse events.
Measured over Through day 8
+8 more outcomes measured

Conditions

COVID-19

Explore related trials

COVID-19 Infection

Where it's being run

8 sites across 8 states
California1
Maryland1
Missouri1
New York1
North Carolina1
Pennsylvania1
Tennessee1
Washington1

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

These criteria apply to females who are in a heterosexual relationship who are of childbearing potential. Not of childbearing potential include post-menopausal females (defined as having a history of amenorrhea for at least one year) or a documented status as being surgically sterile (hysterectomy, bilateral oophorectomy, or tubal ligation/salpingectomy).
True abstinence is 100% of the time, no sexual intercourse (penis enters the vagina). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods.
Acceptable forms of primary contraception include a monogamous relationship with a vasectomized partner who has been vasectomized for 180 days or more before the participant's study product administration, intrauterine devices, birth control pills, and injectable/implantable/insertable/transdermal hormonal birth control products. Must have used at least one acceptable primary form of contraception for at least 30 days before study product administration and agree to continue at least one acceptable primary form of contraception through 60 days after study product administration. 5. Participants of childbearing potential must have a negative urine pregnancy test at screening and within 24 hours before study product administration. 6. In general good health\*.

What this trial measures

  • Occurrence of abnormal clinical safety laboratory adverse events.Through day 8
  • Occurrence of adverse events of special interest (AESIs).Through 6 months
  • Occurrence of medically attended adverse events (MAAEs).Through 6 months
  • Occurrence of new onset chronic medical conditions (NOCMCs).Through 6 months
  • Occurrence of potentially immune-mediated diseases (pIMDs)Through 6 months
  • Occurrence of Serious adverse events (SAEs).Through 6 months
  • Occurrence of solicited local adverse events (AEs).Through 7 days
  • Occurrence of solicited systemic adverse events (AEs).Through 7 days
  • Occurrence of unsolicited adverse events (AEs).Through 28 days